Cargando…

Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients

BACKGROUND: Left subclavian artery revascularization (LSA) is frequently performed in the setting of thoracic endovascular repair (TEVAR). The purpose of this study was to compare different techniques for LSA revascularization during TEVAR. METHODS: We performed a single center’s retrospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Wei, Xue, Yunxing, Li, Shuchun, Jin, Min, Zhou, Qing, Wang, Dongjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325210/
https://www.ncbi.nlm.nih.gov/pubmed/34330305
http://dx.doi.org/10.1186/s13019-021-01593-w
_version_ 1783731521004240896
author Xie, Wei
Xue, Yunxing
Li, Shuchun
Jin, Min
Zhou, Qing
Wang, Dongjin
author_facet Xie, Wei
Xue, Yunxing
Li, Shuchun
Jin, Min
Zhou, Qing
Wang, Dongjin
author_sort Xie, Wei
collection PubMed
description BACKGROUND: Left subclavian artery revascularization (LSA) is frequently performed in the setting of thoracic endovascular repair (TEVAR). The purpose of this study was to compare different techniques for LSA revascularization during TEVAR. METHODS: We performed a single center’s retrospective cohort study from 2016 to 2019. Patients were categorized by LSA revascularization methods, including direct coverage without revascularization (Unrevascularized), carotid-subclavian bypass (CSB), fenestrated TEVAR (F-TEVAR). Indications, demographics, operation details, and outcomes were analyzed using standard statistical analysis. RESULTS: 171 patients underwent TEVAR with LSA coverage, 16.4% (n = 28) were unrevascularized and the remaining patients underwent CSB (n = 100 [58.5%]) or F-TEVAR (n = 43 [25.1%]). Demographics were similar between the unrevascularized and revascularized groups, except for procedure urgent status (p = 0.005). The incidence of postoperative spinal cord ischemia was significantly higher between unrevascularized and revascularized group (10.7% vs. 1.4%; p = 0.032). There was no difference in 30-day and mid-term rates of mortality, stroke, and left upper extremity ischemia. CSB was more likely time-consuming than F-TEVAR [3.25 (2.83–4) vs. 2 (1.67–2.67) hours, p = 0], but there were no statistically significant differences in 30-day or midterm outcomes for CSB versus F-TEVAR. During a mean follow-up time of 24.8 months, estimates survival rates had no difference. CONCLUSIONS: LSA revascularization in zone 2 TEVAR is necessary which is associated with a low 30-day rate of spinal cord ischemia. When LSA revascularization is required during TEVAR, CSB and F-TEVAR are all safe and effective methods, and F-TEVAR appears to offer equivalent clinical outcomes as a less time-consuming and minimally invasive alternative.
format Online
Article
Text
id pubmed-8325210
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83252102021-08-02 Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients Xie, Wei Xue, Yunxing Li, Shuchun Jin, Min Zhou, Qing Wang, Dongjin J Cardiothorac Surg Research Article BACKGROUND: Left subclavian artery revascularization (LSA) is frequently performed in the setting of thoracic endovascular repair (TEVAR). The purpose of this study was to compare different techniques for LSA revascularization during TEVAR. METHODS: We performed a single center’s retrospective cohort study from 2016 to 2019. Patients were categorized by LSA revascularization methods, including direct coverage without revascularization (Unrevascularized), carotid-subclavian bypass (CSB), fenestrated TEVAR (F-TEVAR). Indications, demographics, operation details, and outcomes were analyzed using standard statistical analysis. RESULTS: 171 patients underwent TEVAR with LSA coverage, 16.4% (n = 28) were unrevascularized and the remaining patients underwent CSB (n = 100 [58.5%]) or F-TEVAR (n = 43 [25.1%]). Demographics were similar between the unrevascularized and revascularized groups, except for procedure urgent status (p = 0.005). The incidence of postoperative spinal cord ischemia was significantly higher between unrevascularized and revascularized group (10.7% vs. 1.4%; p = 0.032). There was no difference in 30-day and mid-term rates of mortality, stroke, and left upper extremity ischemia. CSB was more likely time-consuming than F-TEVAR [3.25 (2.83–4) vs. 2 (1.67–2.67) hours, p = 0], but there were no statistically significant differences in 30-day or midterm outcomes for CSB versus F-TEVAR. During a mean follow-up time of 24.8 months, estimates survival rates had no difference. CONCLUSIONS: LSA revascularization in zone 2 TEVAR is necessary which is associated with a low 30-day rate of spinal cord ischemia. When LSA revascularization is required during TEVAR, CSB and F-TEVAR are all safe and effective methods, and F-TEVAR appears to offer equivalent clinical outcomes as a less time-consuming and minimally invasive alternative. BioMed Central 2021-07-30 /pmc/articles/PMC8325210/ /pubmed/34330305 http://dx.doi.org/10.1186/s13019-021-01593-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Xie, Wei
Xue, Yunxing
Li, Shuchun
Jin, Min
Zhou, Qing
Wang, Dongjin
Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title_full Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title_fullStr Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title_full_unstemmed Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title_short Left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
title_sort left subclavian artery revascularization in thoracic endovascular aortic repair: single center’s clinical experiences from 171 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325210/
https://www.ncbi.nlm.nih.gov/pubmed/34330305
http://dx.doi.org/10.1186/s13019-021-01593-w
work_keys_str_mv AT xiewei leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients
AT xueyunxing leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients
AT lishuchun leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients
AT jinmin leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients
AT zhouqing leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients
AT wangdongjin leftsubclavianarteryrevascularizationinthoracicendovascularaorticrepairsinglecentersclinicalexperiencesfrom171patients